Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors

作者：Shen Tian, Hao Li, Renhua Li, Ran Liang, Shu Li, Juan Wu, Zhou Xu, Xinyu Liang, Yuling Chen, Jun Xiao, Jiaying Wei, Chen-yu Ma, Jing-yu Song, Rui-ling She, Kainan Wu, Lingquan Kong · 发表于：Chinese Medical Journal · 年份：2022 · DOI：10.1097/cm9.0000000000002121 · 被引用次数：6 · 研究领域：Liver Disease Diagnosis and Treatment、Diet, Metabolism, and Disease、Alcohol Consumption and Health Effects

To the Editor: Non-alcoholic fatty liver disease (NAFLD) comes to prevail in Asia and the prevalence in China is reported to be 24% to 36%.[1] The prevalence of NAFLD and its associated medical burden might be underestimated. The diagnosis of NAFLD led to the exclusion of other chronic liver diseases including “excess” alcohols, thus the population with alcoholic consumptions or other liver diseases might be neglected. In March 2020, the international expert consensus proposed a new concept, “metabolic associated fatty liver disease (MAFLD),” and replaced the earlier term of “NAFLD.”[2] As the most prevalent female malignancy, breast cancer (BC) shares similar risk factors to MAFLD. Higher levels of obesity and physical inactivity are closely correlated to BC and are significant drive for the increasing trends in the prevalence of BC. Some BC survivors may receive chemotherapy and endocrine therapy, both of which are reported to increase the risk of hepatic steatosis (HS), which is the fundamental criteria of the diagnosis of MAFLD.[2] The prevalence of HS among breast cancer survivors (BCS) is routinely ignored by oncologists and HS is usually diagnosed by conventional liver ultrasonography (US), while liver ultrasound elastography (USE) is increasingly used due to its higher sensitivity and specificity compared to US.[3] Therefore, USE was used in our study to investigate the accurate prevalence of HS and MAFLD among BCS. In this matched cohort study, we enrolled the primar...